Showing results (131-140 of 147) with videos related to

Sort By:
Pageof 15
Journal for Immunotherapy of Cancer|June 17, 2020
Phase IA/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumorsJayesh Desai, Sanjeev Deva, Jong Seok Lee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 17, 2020
Circulating Tumor DNA Predicts Outcome from First-, but not Second-line Treatment and Identifies Melanoma Patients Who May Benefit from Combination ImmunotherapyGabriela Marsavela, Jenny Lee, Leslie Calapre, et al.
The Lancet. Oncology|December 3, 2014
Dacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell lung cancer (NCIC CTG BR.26): a double-blind, randomised, phase 3 trialPeter M Ellis, Frances A Shepherd, Michael Millward, et al.
European Journal of Cancer (Oxford, England : 1990)|October 23, 2018
Anti-PD-1/PD-L1 immunotherapy in patients with solid organ transplant, HIV or hepatitis B/C infectionMartin Tio, Rajat Rai, Ogochukwu M Ezeoke, et al.
Cancer Discovery|April 11, 2022
Sunvozertinib, a Selective EGFR Inhibitor for Previously Treated Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion MutationsMengzhao Wang, James Chih-Hsin Yang, Paul L Mitchell, et al.
Journal for Immunotherapy of Cancer|August 28, 2021
Adjuvant nivolumab for stage III/IV melanoma: evaluation of safety outcomes and association with recurrence-free survivalMario Mandala, James Larkin, Paolo Antonio Ascierto, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 5, 2024
Outcomes With Postrecurrence Systemic Therapy Following Adjuvant Checkpoint Inhibitor Treatment for Resected Melanoma in CheckMate 238Jeffrey Weber, Michele Del Vecchio, Mario Mandalá, et al.
Pigment Cell & Melanoma Research|February 16, 2019
Incidence, features and management of radionecrosis in melanoma patients treated with cerebral radiotherapy and anti-PD-1 antibodiesInes Pires da Silva, Isabella C Glitza, Lauren E Haydu, et al.
European Journal of Cancer (Oxford, England : 1990)|August 14, 2022
Adjuvant nivolumab versus ipilimumab (CheckMate 238 trial): Reassessment of 4-year efficacy outcomes in patients with stage III melanoma per AJCC-8 staging criteriaJames Larkin, Jeffrey Weber, Michele Del Vecchio, et al.
The Lancet. Oncology|September 22, 2020
Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trialPaolo A Ascierto, Michele Del Vecchio, Mario Mandalá, et al.
Pageof 15